Lupin wins USFDA nod for Risperidone for extended-release injectable suspension for schizophrenia

This is Lupin's first product using proprietary Nanomi B.V.'s technology and has a 180-day CGT exclusivity.;

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-09-03 09:00 GMT   |   Update On 2025-09-03 09:00 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced that the company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials.

Risperidone for extended-release injectable suspension is bioequivalent to the reference listed drug (RLD), Risperdal Consta Long-Acting Injection, and is indicated for the treatment of
schizophrenia
and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder.

This is Lupin’s first product using proprietary Nanomi B.V.’s technology and has a 180-day CGT exclusivity.

Nanomi, a Lupin subsidiary, is focused on the development of innovative long-acting injectable (LAI) medicines to improve health outcomes for patients.

Vinita Gupta, CEO of Lupin, said, “We are very pleased with the approval of the first product from our Nanomi LAI platform. This first-cycle approval is a testament to the capabilities we have established for complex injectables across our teams in R&D, Operations and related functions. It validates our platform capabilities at Nanomi and underscores our commitment to expanding access to complex injectables for patients globally. As we execute on our strategy to evolve specialty/novel products, we plan to leverage the Nanomi platform for novel long-acting injectables that meet unmet patient needs.”

Advertisement

Nanomi’s LAI platform has demonstrated efficacy and safety in drug delivery. Its proprietary particle control technology creates uniform microspheres that deliver extended-release profiles from weeks to months, superior injectability through smaller needles, and consistent drug concentrations. The technology can provide lifecycle extension opportunities for products in development or on the market that would benefit from longer-acting formulations.

“Risperidone’s U.S. FDA approval provides crucial validation of Nanomi’s LAI technology platform and testifies to Lupin’s ability to bring complex injectables to market,” said Dr. Shahin Fesharaki, Chief Scientific Officer of Lupin. “This is a critical milestone that validates the capabilities of our crossfunctional teams and constitutes a significant step forward in our journey to develop novel long-acting injectables across various therapeutic areas.”

Risperidone for extended-release injectable suspension (RLD Risperdal Consta) had estimated annual sales of USD 190 million in the U.S. (IQVIA MAT July 2025).

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News